MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 373-379

  Dansin, Eric ^a   Cinieri, Saverio ^b   Garrido, Pilar ^c   Griesinger, Frank ^d   Isla, Dolores ^e   Koehler, Manfred ^f   Kohlhaeufl, Martin ^g  

^a CENTRE OSCAR LAMBRET   (France)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d PIUS HOSPITAL   (Germany)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f GmbH Pharma Biometrie Consulting ^*  (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bevacizumab; Chemotherapy; Non small cell lung cancer; Phase IV; Safety

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CONJUNCTIVAL HEMORRHAGE; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; GINGIVA BLEEDING; HEMATEMESIS; HEMATOCHEZIA; HEMATOTHORAX; HEMATURIA; HEMOPTYSIS; HEMORRHOID HEMORRHAGE; HUMAN; INCIDENCE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; ORAL BLEEDING; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECTUM HEMORRHAGE; STOMACH HEMORRHAGE; TUMOR BLEEDING; TUMOR LOCALIZATION; UPPER GASTROINTESTINAL BLEEDING; VAGINA BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860507572     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.020     Document Type: Article

References (20)

1. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
2. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
3. Reck M., von Pawel J., Zatloukal P., et al. Overall survival with cisplatin/gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
4. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
5. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011, 305:487-494.
6. Crinò L., Dansin E., Garrido P., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL. MO19390): a phase 4 study. Lancet Oncol 2010, 11:733-740.
7. Wozniak A.J., Garst J., Jahanzeb M., et al. Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). Proc Am Soc Clin Oncol 2010, 28:7618a.
8. Hapani S., Sher A., Chu D., et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010, 79:27-38.
9. Langer C.J., Mehta M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005, 23:6207-6219.
10. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872.
11. Carden C.P., Larkin J.M., Rosenthal M.A. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol 2008, 10:624-630.
12. Archer V., Reck M., Sandler A.B., et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. Proc Am Soc Clin Oncol 2008, 26:8114a.
13. Socinski M.A., Langer C.J., Huang J.E., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27:5255-5261.
14. Besse B., Lasserre S.F., Compton P., et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010, 16:269-278.
15. NCCN practice guidelines in oncology: non-small cell lung cancer, v.2.2010.
16. Avastin® (bevacizumab). Summary of Product Characteristics; 2009, available at: [accessed 05.01.10]. http://www.ema.europa.eu/humandocs/PDFs/EPAR/avastin/emea-combined-h582en.pdf.
17. Sandler A.B, Schiller J.H., Gray R., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009, 27:1405-1412.
18. Miller R.R., McGregor D.H. Hemorrhage from carcinoma of the lung. Cancer 1980, 46:200-205.
19. Kumar P., Fischbach N.A., Brahmer J.R., et al. Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): results from ARIES, an observational cohort study (OCS). Proc Am Soc Clin Oncol 2010, 28:7619a.
20. Miller V.A., O'Connor P., Soh C., Kabbinavar F.J. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2009, 27:LBA8002a.